- Trials with a EudraCT protocol (232)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (8)
232 result(s) found for: Gastric (Stomach) Cancer.
Displaying page 5 of 12.
EudraCT Number: 2008-007546-56 | Sponsor Protocol Number: NEO-FLOT | Start Date*: 2009-09-29 | ||||||||||||||||||||||||||
Sponsor Name:Klinikum der Universität München, Campus Großhadern | ||||||||||||||||||||||||||||
Full Title: A Phase II Multicentre Study of perioperative Chemotherapy for resectable Adenocarcinoma of the Gastroesophageal Junction and of the Stomach | ||||||||||||||||||||||||||||
Medical condition: Resectable Adenokarcinoma of the Gastroesophageal Junction and of the Stomach | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000383-28 | Sponsor Protocol Number: CA224-050 | Start Date*: 2019-05-23 | |||||||||||||||||||||
Sponsor Name:University Hospital Essen | |||||||||||||||||||||||
Full Title: Perioperative immunotherapy vs. chemo-immunotherapy stratified by early response evaluation in patients with advanced gastric cancer (GC) and adenocarcinoma of the esophago-gastric junction (AEG) (... | |||||||||||||||||||||||
Medical condition: Histologically confirmed, resectable advanced gastric cancer GC and adenocarcinoma of the esophago-gastric junction | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001967-26 | Sponsor Protocol Number: ACT16444 | Start Date*: 2021-09-16 | ||||||||||||||||
Sponsor Name:Sanofi aventis recherche & développement | ||||||||||||||||||
Full Title: Open-label study of tusamitamab ravtansine (SAR408701) in combination with ramucirumab in participants previously treated for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma with... | ||||||||||||||||||
Medical condition: Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002331-25 | Sponsor Protocol Number: BP27836 | Start Date*: 2011-12-07 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patients with HER2-Positive Advanced Gastric Cancer | |||||||||||||
Medical condition: HER2-positive adenocarcinoma of the stomach or gastroesophageal junction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) BE (Completed) CZ (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001008-14 | Sponsor Protocol Number: AT148006 | Start Date*: 2021-10-25 | |||||||||||
Sponsor Name: ALX Oncology Inc. | |||||||||||||
Full Title: A Phase 2/3 Study of ALX148 in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma | |||||||||||||
Medical condition: Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011337-27 | Sponsor Protocol Number: AGMT Gastric-4 | Start Date*: 2010-05-03 | |||||||||||||||||||||
Sponsor Name:AGMT | |||||||||||||||||||||||
Full Title: A two-stage multicenter phase II trial of concurrent induction chemoimmunotherapy with epirubicine, oxaliplatin, capecitabine and panitumumab in KRAS wild-type, resectable type II gastric adenoca... | |||||||||||||||||||||||
Medical condition: Gastric cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004535-24 | Sponsor Protocol Number: RLY-4008-101 | Start Date*: 2021-07-07 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Relay Therapeutics, Inc. | ||||||||||||||||||||||||||||||||||||||
Full Title: A First-in-Human Study of Highly Selective FGFR2 inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and other Advanced Solid Tumors | ||||||||||||||||||||||||||||||||||||||
Medical condition: Unresectable or metastatic cholangiocarcinoma (CCA), other advanced solid tumors with an FGFR2-alteration or other potential FGFR2-dependent tumors | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: SE (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002240-40 | Sponsor Protocol Number: I4T-MC-JVCU | Start Date*: 2015-04-10 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal ... | |||||||||||||
Medical condition: Metastatic gastric adenocarcinoma or gastroesophageal junction (GEJ) denocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) FI (Completed) NL (Completed) IT (Completed) ES (Completed) PL (Completed) BE (Completed) GB (Completed) CZ (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001526-19 | Sponsor Protocol Number: BO27798 | Start Date*: 2011-12-28 | ||||||||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A randomized, open-label, multicenter Phase IIIb study comparing two trastuzumab dosing regimens, each in combination with cisplatin/ capecitabine chemotherapy, as first-line therapy in patients wi... | ||||||||||||||||||
Medical condition: Metastatic HER2-positive adenocarcinoma of the stomach or gastro-esophageal junction. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) PL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003791-23 | Sponsor Protocol Number: I4T-MC-JVDB | Start Date*: 2015-04-23 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Protocol I4T-MC-JVDB Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second Line Gastric or Gastroesophageal Junction Adenocarcinoma | |||||||||||||
Medical condition: Second Line Gastric or Gastroesophageal Junction Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) FR (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004693-34 | Sponsor Protocol Number: GOIRC 02/2007 | Start Date*: 2007-12-20 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA | |||||||||||||
Full Title: Multicenter, phase II study of chemotherapy with dose-dense modified TCF in locally advanced or metastatic gastric cancer. | |||||||||||||
Medical condition: Patients with locally advanced or metastatic gastric cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002697-35 | Sponsor Protocol Number: TEX | Start Date*: 2008-06-10 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI PARMA | |||||||||||||
Full Title: A dose-finding study of Docetaxel, Oxaliplatin and Capecitabine (TEX) as First-Line Treatment in Patients with Advanced Gastric Cancer | |||||||||||||
Medical condition: Patients with Advanced Gastric Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005748-12 | Sponsor Protocol Number: 2012.761 | Start Date*: 2013-04-26 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: D2 Resection and HIPEC (Hyperthermic intraperitoneal chemoperfusion) in locally advanced gastric carcinoma. A national randomized and multicentric phase III study | |||||||||||||
Medical condition: Gastric adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001843-25 | Sponsor Protocol Number: BNT141-01 | Start Date*: 2023-02-23 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:BioNTech SE | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT141 as a monotherapy and... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: CLDN18.2-positive solid tumors | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) ES (Prematurely Ended) NL (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002595-27 | Sponsor Protocol Number: 58258 | Start Date*: 2017-05-30 | |||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||
Full Title: Cytoreductive surgery and Intraperitoneal chemotherapy and for Stomach CAncer: a feasibility study | |||||||||||||
Medical condition: Peritoneal carcinomatosis of gastric origin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005725-29 | Sponsor Protocol Number: EGF110656 | Start Date*: 2008-05-09 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development | |||||||||||||
Full Title: A Phase III Study of ErbB2 Positive Advanced or Metastatic Gastric or Esophageal Or Gastroesophageal Junction Adenocarcinoma Treated with Capecitabine Plus Oxaliplatin with or without Lapatinib | |||||||||||||
Medical condition: Subjects with ErbB2-positive advanced or metastatic gastric or oesophageal or gastro-oesophageal junction adenocarcinoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) IT (Completed) NL (Ongoing) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004500-22 | Sponsor Protocol Number: GOIRC-01-2017 | Start Date*: 2018-03-02 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | |||||||||||||
Full Title: Phase II multicentre trial of perioperative chemotherapy in operable patients with gastric cancer (PERISCOPE trial) | |||||||||||||
Medical condition: Gastric Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002844-10 | Sponsor Protocol Number: CA209-032 | Start Date*: 2013-11-12 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors | ||||||||||||||||||||||||||||||||||||||
Medical condition: Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovari... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Ongoing) FI (Completed) IT (Completed) DK (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002464-27 | Sponsor Protocol Number: IEOS707/412 | Start Date*: 2013-06-26 | ||||||||||||||||||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | ||||||||||||||||||||||||||||
Full Title: Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients with solid tumors metastatic or relapsed, resistant/refractory to conventional therapy, using HLA-identical related donors or H... | ||||||||||||||||||||||||||||
Medical condition: solid tumors metastatic or relapsed, resistant/refractory to conventional therapy | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005067-32 | Sponsor Protocol Number: I4T-MC-JVCZ | Start Date*: 2015-11-24 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Protocol I4T-MC-JVCZ Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination with Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gast... | |||||||||||||
Medical condition: Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) SE (Completed) GR (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
